SCHEMBL4059241

SCHEMBL4059241

CC1(c2ccccc2)CC(=O)CN1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.40
ALDH1A1 P00352 2/20 0.38
CYP2C9 P11712 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C19 P33261 1/20 0.37
LMNA P02545 1/20 0.36
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
HCAR3 P49019 1/20 0.34
HCAR2 Q8TDS4 1/20 0.34
MMP1 P03956 1/20 0.34
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
DRD2 P14416 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
ADRB2 P07550 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
KIF11 P52732 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4977216 0.76 ALDH1A1 (0.36) BACE1ALDH1A1CYP2C9LMNAMEN1
SCHEMBL14095713 0.74 ALDH1A1 (0.36) BACE1ALDH1A1CYP2C9CYP1A2CYP2C19
SCHEMBL21245148 0.72 GAA (0.33) ALDH1A1MEN1KMT2A
SCHEMBL908982 0.71 HSD11B1 (0.44) ALDH1A1MEN1KMT2ANPSR1
SCHEMBL30338318 0.70 MEN1 (0.47) ALDH1A1LMNAMEN1KMT2ASIGMAR1
SCHEMBL13655884 0.70 BACE1 (0.35) BACE1ALDH1A1CYP2C9CYP1A2CYP2C19
SCHEMBL23858690 0.69 KDM4E (0.33) ALDH1A1
SCHEMBL23858688 0.69 KDM4E (0.33) ALDH1A1
SCHEMBL4062614 0.69 CCR2 (0.38) ALDH1A1LMNAMEN1KMT2A
SCHEMBL4067819 0.69 CCR2 (0.38) ALDH1A1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1515724-B1 MITOTIC KINESIN INHIBITORS MERCK & CO INC (US) 2009-10-21 EP disclosed
US-7348440-B2 Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator MERCK & CO., INC. (US) 2008-03-25 US disclosed
US-20060105997-A1 Mitotic kinesin inhibitors MERCK SHARP & DOHME CORP. 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060105997-A1 Mitotic kinesin inhibitors KIF5B, KIF2C, KIF18B BACE1 4085/4885ALDH1A1 2371/4885CYP2C9 4867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.